News Innate and BMS' immunotherapy fails in phase 2 trial French biotech developing cancer immunotherapy with BMS.
News Opdivo still clear immunotherapy leader despite Keytruda gai... Immunotherapy takes on rivals from Roche and BMS.
News Pfizer breast cancer drug Ibrance rejected by NICE Ibrance too expensive at almost £80,000 per course.
News Takeda preps for further acquisition Japanese firm has set money aside for emerging markets M&A.
News EU clears first drug therapy for rare disease cALD Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
